masthead-publications

Categories

Filter by Topics

ABC-DLBCL ADCC Gene Alteration Airway Remodeling AKT Targeted Therapy ALK Alleles Angiogenesis Anti-TNF Alpha Therapy Anus Apoptosis AR-Specific T Cells Asthma Autocrine Signaling Autoimmune Disorder AXL B-cell lines B-cell lymphoma Biofluid Biology of neoplasia Biomarker Biomarker Analysis Biomarker Discovery Biomarker Patient Stratification Biomarker Validation Biomarkers Biomarkers Outcome Bladder Bladder Cancer blood Brain Brain RNA Breast Breast Cancer Cancer Immune Response Carcinoma Cardio Vascular Disease cardiovascular disease CD-19 CD44 CDKN2A mutation Cell line Cells Cerebral Spinal Fluid Checkpoint Inhibitors Chemoresistance Chronic Obstructive Pulmonary Disease Circulating miRNAs Circulating Tumor Cells Classification Clinical Outcome Prediction Clinical Trials cMET Coccidioidomycosis Colon Colon cancer Colorectal cancer Comparative Approach Comparative Study Comparison study Comprehensive Gene Expression Study Cord Blood Buffy Coat Core Needle Biopsy Custom mRNA Cyclin E mRNA Cytokines Detection Developmental Immunotherapy Diabetes Diagnostic Biomarkers Differential Diagnosis Differential Expression Differential Gene Expression Analysis Diffuse large B-cell lymphoma Dissecting Genomic Biomarkers DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT EMT-mediated resistance Encephalophy Epidemiology outcomes Epigenetics Epigenomic Epstein-Barr ERBB2 Esophageal Cancer Exosomes Extracellular Vesicles Extracted RNA Fabry Disease Feasibility FFPE FFPE Canine Tumor FGF Ligand Trap FGFR Fibrous Tumors Gastrointestinal Cancers Gene Expression Analysis Gene Expression Comparisons Gene Expression Profiling Gene Expression Signatures Gene Fusions Gene Pathway Analysis Genetic Polymorphism Genomic Genomic Bioinformatics Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel Human Human serum Hypoxia Immune Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune Tolerance Immune-checkpoint blockade Immune-related Colitis Immuno-Oncology Immunofluorescence Immunology Immunotherapy Induction Chemotherapy Inflammation Inflammatory Signatures Interferon Gamma Signature Invasive Breast Carcinoma Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver Lung Lung Adenocarcinoma Lung cancer Lung Carcinoma Lupus Lymph Node Metastasis Lymphoma Mechanism of Action Melanoma Mesothelioma MET Metastatic Colon Cancer Metastatic Prostate Cancer Methods Comparison Mice Mice PDX Microenvironment miRNA miRNA WTA miRQC study Molecular Characterization Mouse Mouse mRNA mRNA mRNA custom mRNA expression in tumors mTOR pathway mTORC1 mTORC2 Mucin Hypersecretion Multiple Myeloma Muscle Mutations MYC Myocardial Reperfusion Myocarditis NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Nivolumab non-Hodgkin Lymphoma Non-small Cell Lung Cancer Novel Therapeutic Targets NSCLC NTRK1 Oesophageal Adenocarcinoma Oncogenes Oncology Oncomirs Oral Cancer Oral Squamous Cell Carcinoma Osteoclast Ovarian cancer Overexpression P13KmTOR Inhibitor Palbociclib Pancreas Pancreatic Cancer Pancreatic ductal adenocarcinoma Pancreatic Ductal Adenocarcinoma Paralysis Parkinson's Disease Pathogenesis Pathology Pathway Analysis Pathways PCA Cell Lines PD-1 Pd-L1 PD-L1 Phase 3 clinical trial PI3K signaling pathway PIK3CA mutation Plasma plasma Platform Comparison Pralatrexate predictive Predictive Biomarkers Predictive Modeling Pro-inflammatory cytokines Profiling Profiling Signature Development Prognostic Prognostic Biomarkers Programmed cell death protein 1 Programmed death ligand 1 Progression free-survival Prostate Prostate Cancer qNPA qPCR Radiation Toxicities Radioimmunotherapy Rearrangements rectum Regulation Renal Cell Carcinoma Renal Disease Responders vs Non-responders Response rate RET Reveal Rheumatoid Arthritis Risk Score Rituximab ROS1 safety Sarcoidosis Sarcoma SCBC SCLC Serum Signaling Inhibitors Signaling Pathways Signature Development Signature Pathway Analysis Signature Validation Signatures Sinonasal Undifferentiated Carcinoma Skin Small bowel Small cell bladder cancer Small Cell Bladder Cancer Small Cell Lung Cancer SPECS Lung Consortium Squamous cell carcinoma Sub-typing Surveillance Survival Outcomes Survival plots Synovial Fluid System Validation Systemic Lupus Erythematousus T cell T-cells Technology Comparison Therapeutic Response Therapeutic targets Tissue-based biomarkers TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Triple Negative Breast Cancer Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Mutational Burden tumor mutational burden Type 1 diabetes Urothelial carcinoma Uveal melanoma VEGFR Venetoclas Vistusertib WNT Path Signaling Xenograft Tissue

2019

A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL

Eyre, T. A., et al. A phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 Inhibitor Vistusertib in Relapsed, Refractory DLBCL. Hematological Oncology 2019; 37:352-359.

Download pdf 1.7MB

The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination

Tarantelli, C., et al. The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination. Paper presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland.  Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.90_2629

View External Link

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

Hicks, S. W., et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Hematologica. 2019 Feb 7; 104(8):1633-1639

Download pdf 1.5MB

Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

Ansell, S. M., et al. Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Journal of Clinical Oncology. 2019 Jan 8:37(6):481-489

Download pdf 873KB

2018

Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples.

Schaffer, M., et al. Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples. J Mol Biomark Diagn 2018, 9:2 DOI: 10.4172/2155-9929.1000386

Download pdf 1.3MB

Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial

Richter, J.  et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Poster Presented at: ASH Annual meeting session 626. 2018 Dec 3. San Diego, CA

Download pdf 1.1MB
View External Link

Cell-of-origin classification of diffuse large B-cell lymphoma - comparison of molecular tests and extension to the PETAL trial

Richter, J. et al, Cell-of-origin classification of diffuse large B-cell lymphoma - comparison of molecular tests and extension to the PETAL trial. Abstract presented at: 102nd Annual Meeting of the German Society for Pathology 2018 May 24 – 16; Berlin, Germany Abstract, #AG02.16

Download pdf 121KB

PQR309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy.

Bertoni, F., et al. PQ309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy. Clin Cancer Res. Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24. [Epub ahead of print].

PMID: 29066507

View External Link

2017

2016

Page last updated March 10, 2020